With multiple recent approvals of biologics to treat psoriasis Cosentyx (secukinumab, Novartis AG), Ilumya (tildrakizumab-asmn, Sun Pharmaceutical Industries Ltd.), Taltz (ixekizumab, Eli Lilly and Co.) and others companies are turning to topical treatments to capture the estimated 80 percent to 90 percent of psoriasis patients with mild to moderate disease where cheaper topical medications are more appropriate. Read More
When it comes to sensory functions, the eyes have been the focus of much attention from researchers and drug developers, resulting in last year's breakthrough for Spark Therapeutics Inc. with the FDA nod for gene therapy Luxturna (voretigene neparvovec-rzyl) to treat children and adults with confirmed biallelic RPE65 mutation-associated retinal dystrophy, an ultra-rare disease that leads to vision loss and, sometimes, blindness. Read More
